ライフサイエンスコーパス: mass cytometry

1 h-dimensional mass cytometry (time-of-flight mass cytometry).

2 g functionalized beads readily detectable by mass cytometry.

3 detected in patient tissue samples by using mass cytometry.

4 RNA and proteins were identified by imaging mass cytometry.

5 d this pattern of localization using imaging mass cytometry.

6 3(+)CD4(+) T cell populations by single-cell mass cytometry.

7 llular systems has fueled the development of mass cytometry.

8 n genetically engineered cancer models using mass cytometry.

9 nd cancer cell subsets from fluorescence and mass cytometry.

10 ll carcinomas can be reliably dissected with mass cytometry.

11 ing intravital microscopy and time-of-flight mass cytometry.

12 cyte populations in PBMC, were analyzed with mass cytometry.

13 owerful new single-cell technologies such as mass cytometry.

14 ripheral blood mononuclear cells measured by mass cytometry.

15 okine profile by highly multiplexed flow and mass cytometry.

16 protein expression comparable to those from mass cytometry.

17 agnosed AML and healthy subjects (n = 18) by mass cytometry.

18 with T-cell receptor repertoire analysis and mass cytometry.

19 ater resolution using polychromatic flow and mass cytometry.

20 noparticles are also of profound interest in mass cytometry.

21 from dengue patients in India, measured with mass cytometry.

22 ucleotides with lanthanide metals for use in mass cytometry.

23 measure at least 27 specific RNAs by flow or mass cytometry.

24 Here we use imaging mass cytometry(5) to simultaneously quantify 35 biomarke

25 Using mass cytometry, a high-dimensional technique that can pr

26 Here we used mass cytometry, a technique that combines single cell an

27 Additionally, we introduce imaging mass cytometry, a technique that couples the power of ma

28 Like flow and mass cytometry, Abseq uses specific antibodies to detect

29 Recent advances in mass cytometry allow simultaneous measurements of up to

30 Mass cytometry allows for simultaneous measurement of >4

31 /2009 (H1N1) virus challenge monitored using mass cytometry along with other clinical assessments.

32 emental (heavy metal) reporter ions, such as mass cytometry (also known as CyTOF) and analogous high-

33 Mass cytometry analyses of peripheral blood from melanom

34 Mass cytometry analyses of splenocytes showed a signific

35 d with a 33-metal-labeled antibody panel for mass cytometry analyses of the early chromatin modificat

36 Further mass cytometry analysis identified an EOMES(+)CD69(+)CD4

37 Finally, mass cytometry analysis of 8 IFN-inducible phosphoepitop

38 , we have employed 38-channel time-of-flight mass cytometry analysis to generate comprehensive immune

39 es the utility and power of high-dimensional mass cytometry analysis to interrogate the cellular inte

40 Using mass cytometry and a highly multiplexed peptide-HLA (hum

41 Here, we used single-cell mass cytometry and absolute quantification by mass spect

42 with early MS using multiplexed single-cell mass cytometry and algorithm-based data analysis.

43 We combine the depth of single-cell mass cytometry and an algorithm developed to leverage th

44 Using mass cytometry and an unbiased multidimensional analytic

45 lammatory/autoimmune complications) by using mass cytometry and flow cytometry.

46 Using mass cytometry and gene expression analyses, we identifi

47 arenchymal cells were immunophenotyped using mass cytometry and gene expression analyses.

48 Airway eosinophils were characterized using mass cytometry and grouped into subpopulations using uns

49 w, by integrating MHC tetramer multiplexing, mass cytometry and high-dimensional analyses, that neoan

50 gland biopsy specimens were also analyzed by mass cytometry and immunohistochemistry.

51 gether, our study shows the power of imaging mass cytometry and its ability to both quantify immune c

52 macological and genetic strategies alongside mass cytometry and multiplex immunofluorescence techniqu

53 Using mass cytometry and network analysis, we demonstrate that

54 f MSI and other single-cell modalities (e.g. mass cytometry and next-generation sequencing).

55 Single-cell mass cytometry and prospective isolation show that these

56 nd malignant hematopoietic cells analyzed by mass cytometry and provide recommendations for appropria

57 number of measurement channels available for mass cytometry and reduces interference with lanthanide-

58 Combining HLA-DQ-gluten tetramers with mass cytometry and RNA sequencing analysis, we find that

59 Time-of-flight mass cytometry and RNA sequencing were used to character

60 obtained before and after challenge by CyTOF mass cytometry and RNAseq.

61 We apply our method to mass cytometry and scRNA-seq datasets, and demonstrate t

62 rences in protein versus RNA expression from mass cytometry and scRNA-seq, validated by immunohistoch

63 Through mass cytometry and single-cell RNA sequencing (RNA-seq)

64 Through mass cytometry and single-cell RNA sequencing, we identi

65 veral novel biological technologies, such as mass cytometry and single-cell RNA-seq (scRNA-seq), are

66 s of cell subset activation was performed by mass cytometry and spectral cytometry.

67 nophenotyping using both public and in-house mass cytometry and spectral flow cytometry datasets.

68 Combining mass cytometry and transcriptomics revealed cell states

69 tracking cell proliferative history through mass cytometry and uncouple division, time and regulator

70 d beads for signal spillover compensation in mass cytometry, and, strikingly, their application in qu

71 42592) in which we employ a high-dimensional mass cytometry approach to characterize innate and adapt

72 We used a single-cell mass cytometry approach to comprehensively and functiona

73 Flow cytometry and mass cytometry are complementary to each other; however,

74 dimensional single-cell technologies such as mass cytometry are enabling time series experiments to m

75 le-cell analyses based on flow cytometry and mass cytometry are important for investigations of disea

76 Flow cytometry and mass cytometry are widely used to diagnose diseases and

77 urther, this study highlights time-of-flight mass cytometry as a reliable method for immunophenotypin

78 This review will cover the basics of mass cytometry as well as outline assays developed for t

79 Existing mass cytometry barcoding approaches require time intensi

80 Using a mass cytometry-based systems approach, we comprehensivel

81 Here we couple mass-cytometry-based single-cell analysis with overexpre

82 We previously developed a mass-cytometry-based single-cell proteomics approach tha

83 lied single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA sequencing (RNA-seq) and flow c

84 an increase in percentage of CAR T cells by mass cytometry by time of flight (CyTOF); 3 of 4 of thes

85 Cutting-edge mass cytometry by time-of-flight (CyTOF) can profoundly

86 We used mass cytometry by time-of-flight (CyTOF) to model this p

87 Mass cytometry by time-of-flight experiments allow analy

88 Here we demonstrate that mass cytometry by time-of-flight provides a label-free a

89 Here, we used a novel technology, mass cytometry by time-of-flight, to comprehensively cha

90 ntreated mice as assessed by high-definition mass cytometry by time-of-flight.

91 Furthermore, mass cytometry can enumerate AuNPs with a lower detectio

92 igh dimensional immune (HDI) profiling using mass cytometry combined with other measures of vaccinati

93 scope of information that can be obtained by mass cytometry continues to increase, particularly due t

94 Novel techniques such as mass cytometry could help to identify melanoma biomarker

95 nomatous polyposis coli (APC) time-of-flight mass cytometry (CyTOF analysis).

96 e case of highly multiplexed methods such as mass cytometry (CyTOF) able to correlate the levels of m

97 ell populations, we performed time-of-flight mass cytometry (CyTOF) analysis of CD45-expressing immun

98 Using mass cytometry (CyTOF) and next-generation sequencing of

99 Mass cytometry (CyTOF) has greatly expanded the capabili

100 mal RNA (rRNA) sequencing and time-of-flight mass cytometry (CyTOF) immunophenotyping generate data t

101 Mass cytometry (CyTOF) is a technology that has revoluti

102 Mass cytometry (CyTOF) is being used to increase the num

103 CMV (MCMV) infection, we created a 36-marker mass cytometry (CyTOF) panel to investigate how these in

104 metry by time-of-flight mass spectrometry or mass cytometry (CyTOF) studies from the open-access ImmP

105 We used mass cytometry (CyTOF) to characterize and compare immun

106 specific flow cytometry and high-dimensional mass cytometry (CyTOF) to compare BCR signaling response

107 er frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain d

108 ot (ELISPOT), flow cytometry, time-of-flight mass cytometry (CyTOF), and single-cell sequencing enabl

109 Using mass cytometry (CyTOF), we identified major subpopulatio

110 nder homeostatic and stress conditions using mass cytometry (CyTOF)-based single-cell protein analysi

111 Herein, we performed the first mass cytometry (CyTOF)-based, immunophenotyping analysis

112 rosis (RRMS) by high-dimensional single-cell mass cytometry (CyTOF).

113 We employed mass cytometry (cytometry by time of flight, CyTOF) to b

114 ntracellular signals were investigated using mass cytometry (cytometry by time-of-flight), which demo

115 y review some frequently used and accessible mass cytometry data analysis tools, including principal

116 tool for analyzing multidimensional flow and mass cytometry data and to producing heuristic results f

117 We apply ACCENSE to 35-parameter mass cytometry data from CD8(+) T cells derived from spe

118 Dimensionality reduction of Mass Cytometry data further support these findings.

119 ge of examining, visualizing, and presenting mass cytometry data has motivated continuous development

120 However, the high dimensionality of mass cytometry data introduces computational challenges

121 ruct an extensible immune reference map from mass cytometry data of cells from different organs, inco

122 w cytometry data of mouse bone marrow and to mass cytometry data of human bone marrow.

123 We also tested our approach on single-cell mass cytometry data of IFNgamma-stimulated THP1 cells wi

124 very methods on a large collection of public mass cytometry data sets, measuring intra-cellular signa

125 RNA sequencing and high-dimensional flow or mass cytometry data using the full probability distribut

126 When comparing biological conditions using mass cytometry data, a key challenge is to identify cell

127 nd minimizes unwanted cell doublet events in mass cytometry data, and it reduces wet work and Ab cons

128 mining tools that have been used to analyze mass cytometry data, outline their differences, and comm

129 Using 30-channel mass cytometry data, we show that Wishbone accurately re

130 Through unsupervised analyses of mass cytometry data, we show yellow fever virus-specific

131 solved or misleading maps of fluorescent and mass cytometry data.

132 pulations and highlights novel cell types in mass cytometry data.

133 machine learning to facilitate processing of mass cytometry data.

134 -SNE) algorithm, for categorical analysis of mass cytometry data.

135 ral such tools have been applied recently to mass cytometry data.

136 et algorithm applied to the high-dimensional mass cytometry dataset identified a cross-validated mode

137 With a pilot mass cytometry dataset of 2 million cells from 28 gliobl

138 In three mass cytometry datasets, with the largest measuring hund

139 scriminant analysis (LDA)) are tested on six mass cytometry datasets.

140 Mass cytometry defined a systems-level reference framewo

141 Mass cytometry demonstrates a 3-fold expansion of memory

142 Multiparametric single-cell mass cytometry demonstrates that, instead of preferentia

143 Mass cytometry enables an unprecedented number of parame

144 Mass cytometry enables highly multiplexed profiling of c

145 The advent of mass cytometry enables simultaneous assessment of vastly

146 However, the success of mass cytometry experiments depends on fully understandin

147 Mass cytometry facilitates high-dimensional, quantitativ

148 Mass cytometry facilitates high-dimensional, quantitativ

149 ched organoid cultures and native tissues by mass cytometry for 38 markers provide a higher resolutio

150 Here we applied multiplexed mass cytometry for a comprehensive characterization of p

151 This provides a framework for the use of mass cytometry for multiplexed enzyme activity detection

152 ity of a deep immune profiling approach with mass cytometry for the identification of clinically rele

153 ve lanthanide-labeled probes compatible with mass cytometry giving us the ability to monitor the acti

154 The advent of mass cytometry has led to an unprecedented increase in t

155 Mass cytometry has recently emerged as a promising tool

156 Although mass cytometry has some shortcomings such as inability t

157 ogies such as single-cell RNA sequencing and mass cytometry have enabled interrogation of cell type-s

158 igh-throughput technologies such as flow and mass cytometry have the potential to illuminate cellular

159 l single-cell proteomic assays such as Image Mass Cytometry (IMC) and Co-Detection by Indexing (CODEX

160 immunohistochemistry is limited but imaging mass cytometry (IMC) enables the quantification of furth

161 escence microscopy of rhodamine, and imaging mass cytometry (IMC) of gadolinium.

162 Here, we used imaging mass cytometry (IMC) to enable the simultaneous imaging

163 The first application of imaging mass cytometry (IMC) with 3D cell culture enabled single

164 tiplexed ion beam imaging (MIBI) and imaging mass cytometry (IMC)), have been developed from their lo

165 flight (MIBI-TOF) mass spectrometry, imaging mass cytometry (IMC), and flow cytometry-based CyTOF.

166 red mass spectrometry imaging (MSI), imaging mass cytometry (IMC), multiplex immunofluorescence micro

167 strategies are explained, including imaging mass cytometry (IMC), multiplexed ion beam imaging (MIBI

168 ive cohort study, we used a highly multiplex mass cytometry immunoassay to perform an in-depth analys

169 By leveraging combined mass cytometry, immunohistochemistry, and RNA sequencing

170 ctionality probe for both flow cytometry and mass cytometry in a mimetic cell mixture and human perip

171 n high-dimensional cell profiling studies by mass cytometry in biomedical research.

172 ched healthy controls using high-dimensional mass cytometry in combination with algorithm-guided data

173 CD8+ T cells using high-content, single-cell mass cytometry in combination with peptide-loaded MHC te

174 With the expanding applications of mass cytometry in medical research, a wide variety of cl

175 ss some general considerations for deploying mass cytometry in the context of vaccine development.-Re

176 Application and utility of mass cytometry in vaccine development.

177 Here, we used mass cytometry including a broad range of surface marker

178 As new technologies such as mass cytometry increase the parameterization of single-c

179 Imaging mass cytometry indicated that memory-like CD4(+) T cells

180 Mass cytometry is a highly multiparametric proteomic tec

181 Mass cytometry is a new technology that promises to exte

182 mbers of isotopes can be employed as labels, mass cytometry is a powerful analytical technique for mu

183 Implementing bead-based assays in mass cytometry is desired but hampered by the lack of an

184 Mass cytometry is developing as a means of multiparametr

185 ut and cost-effective technique, serology by mass cytometry may contribute to the effective managemen

186 ons was prepared as a potential mass tag for mass cytometry (MC) applications.

187 Mass cytometry (MC) has been developed for high-dimensio

188 Mass cytometry (MC) is a bioanalytical technique that us

189 Mass cytometry (MC) measures metal isotope signals from

190 he combination of machine-learning tools and mass-cytometry measurements of more than 30 protein mark

191 cent advances in high-throughput sequencing, mass cytometry, microfluidics and computational biology

192 Here, we use exploratory mass cytometry (n = 23) and next-generation sequencing (

193 ANA+ healthy, or have SLE using single cell mass cytometry, next-generation RNA-sequencing, multiple

194 Simultaneous analysis by mass cytometry of 28 PTMs in >1 million single cells der

195 This study combined single-cell mass cytometry of paired peripheral and umbilical cord b

196 First, we performed mass cytometry of peripheral blood mononuclear cells and

197 The capabilities of mass cytometry offer expanded potential for deciphering

198 imensional single-cell technologies, such as mass cytometry, offer an opportunity to characterize sig

199 ndation for the incorporation of single-cell mass cytometry on the experimental pipeline.

200 Mass cytometry or CyTOF is an emerging technology for hi

201 multi-dimensional single-cell data, such as mass cytometry or RNA-Seq data, as input and orders cell

202 -cell datasets obtained from flow cytometry, mass cytometry or single-cell RNA sequencing (scRNAseq)

203 nce can then be detected by heavy metal (for mass cytometry)- or fluorophore (for flow cytometry)-con

204 flow cytometry beads into beads suitable for mass cytometry, our approach paves the way toward the br

205 sayed by 62-plex Luminex panel, 40-parameter mass cytometry panel, and 540,000 transcript expression

206 panded and maintained an ML multidimensional mass cytometry phenotype for >3 months.

207 cells and their activation, demonstrated by mass cytometry phosphoproteomics.

208 When used with mass cytometry, PLAYR allowed for the simultaneous quant

209 Mass cytometry presents an exceptional opportunity to in

210 ty of results obtained from high-dimensional mass cytometry profiling data.

211 d that single-cell analysis with time course mass cytometry provided a rapid means of assessing CAR-T

212 In conclusion, the use of single-cell mass cytometry provides a systems-level characterization

213 This fusion of the two technologies, termed mass cytometry, provides measurement of over 40 simultan

214 this Primer, we review the current state of mass cytometry, providing an overview of the instrumenta

215 ts were enrolled for clinical evaluation and mass cytometry quantification of 34 protein markers in b

216 Mass cytometry reagents are probes tagged with metal iso

217 parametric data generated via time-of-flight mass cytometry requires novel analytical techniques beca

218 gical responses were assessed in PBMCs using mass cytometry.RESULTSA total of 19 patients were enroll

219 Profiling of human NK cell subsets by mass cytometry revealed a highly similar expression patt

220 nked glycans (MGL ligands), high-dimensional mass cytometry revealed a wide heterogeneity of infiltra

221 expressing cells in AML vs healthy donors by mass cytometry revealed expression of unique cell-surfac

222 Single cell mass cytometry revealed that c-Jun activates multiple si

223 Compared to flow or mass cytometry, scRNA-Seq could potentially identify cel

224 Mass cytometry showed that switched memory B cells were

225 ed with TLR ligands and analyzed by means of mass cytometry simultaneously for surface marker express

226 It was initially developed for flow and mass cytometry single-cell data.

227 -cell technologies, such as multidimensional mass cytometry, single-cell gene expression, and single-

228 Here we combined functional assays with mass cytometry, single-cell RNA sequencing and high-thro

229 e to a wide variety of data types, including mass cytometry, single-cell RNA sequencing, Hi-C and gut

230 ess in methods such as mass spectrometry and mass cytometry, single-molecule protein identification r

231 Mass cytometry studies demonstrate that cell surface phe

232 Biodistribution and mass cytometry studies demonstrated that MEx localize in

233 In this article, we review published mass cytometry studies relevant to vaccine development,

234 alyzed in 9 single-cell RNA sequencing and 2 mass cytometry studies.

235 pplication of single-cell RNA sequencing and mass cytometry technologies to the study of immune cell

236 tometry, but also show better performance in mass cytometry than the commercially available counterpa

237 plexed transcript quantification by flow and mass cytometry that is compatible with standard antibody

238 As compared to flow and mass cytometry, the high per cell cost of current dsc-se

239 ag cellular barcoding (MCB), which increases mass cytometry throughput by using n metal ion tags to m

240 orm a step-by-step analysis of a single-cell mass cytometry time course dataset from mouse embryonic

241 s, immunohistochemistry, hydroxyproline, and mass cytometry time of flight assays.

242 itions both on synthetic data, as well as on mass cytometry time series of iPSC reprogramming of a fi

243 Using mass cytometry time-course analysis, we resolve lung can

244 ge subsets were examined by high-dimensional mass cytometry (time-of-flight mass cytometry).

245 This first application of mass cytometry to a well-stratified clinical cohort and

246 Here we use mass cytometry to analyse activated T cells in joint tis

247 Using time-of-flight mass cytometry to characterize AMs, a significantly decr

248 We also use viSNE and mass cytometry to compare leukemia diagnosis and relapse

249 To address these issues, we utilized mass cytometry to comprehensively profile the effects of

250 Here, we employ high-dimensional mass cytometry to define the circulating immune cell sig

251 In this study, we used mass cytometry to define the systemic immune landscape i

252 Herein, we use single-cell mass cytometry to dissect the effects of graphene oxide

253 In this study, we used mass cytometry to examine the complexity of human Tregs

254 We applied class II tetramer reagents and mass cytometry to investigate the ontogeny of different

255 We used mass cytometry to measure surface marker expression on p

256 lopment, briefly compare immune profiling by mass cytometry to other systems-level technologies, and

257 We used mass cytometry to perform in-depth characterization of c

258 ulation of CD4+ naive T-cell turnover, using mass cytometry to profile candidate signaling pathways i

259 Several studies have used mass cytometry to profile protective immune responses, b

260 Here, we use high-dimensional mass cytometry to profile protein expression and secreto

261 We used mass cytometry to profile T cells generated in the genet

262 Here, we use mass cytometry to show that metformin treatment expands

263 Here, we use mass cytometry to show that two recently defined human n

264 Using mass cytometry to simultaneously measure multiple signal

265 We now describe experiments in which we used mass cytometry to simultaneously measure multiple surfac

266 We used mass cytometry to simultaneously measure the levels of e

267 We used mass cytometry to study immune cells from nasal biopsy s

268 from Lavin et al. and Chevrier et al. employ mass cytometry to study immune infiltrates in lung adeno

269 We used single-cell "mass cytometry" to examine healthy human bone marrow, me

270 ingle-cell RNA-sequencing and time-of-flight mass cytometry, to identify microglia states in the huma

271 As assessed by time-of-flight mass cytometry, total macrophages were more abundant in

272 f spillover and NSB provide a gateway to use mass cytometry unequivocally to characterize rare cells

273 When analyzed by mass cytometry, up to 40 variables (with scope for futur

274 Mass cytometry, used together with these innovative anal

275 resented to make them most meaningful to the mass cytometry user community.

276 Because mass cytometry uses a set of lanthanide-tagged antibodie

277 rase chain reaction; tumors were analyzed by mass cytometry using markers to detect T cells and other

278 Mass cytometry was used to characterize innate and T-cel

279 In this study, mass cytometry was used to demonstrate a significant inc

280 Mass cytometry was used to investigate the effect of CMV

281 ular reprogramming at the single-cell level, mass cytometry was used to simultaneously measure marker

282 Using mass cytometry, we also find increased frequencies of im

283 Using mass cytometry, we analyze leukocyte subsets, characteri

284 ourse, and outcome remains poor.METHODSUsing mass cytometry, we assessed the immune landscape in long

285 Here, using mass cytometry, we characterise five main dILC subsets:

286 Finally, using imaging mass cytometry, we find that tonsil CD14(+) macrophages

287 Using mass cytometry, we found that NKR expression patterns di

288 By time-of-flight mass cytometry, we found that the TME was enriched in re

289 Using multiparametric phospho-flow and mass cytometry, we measured the intracellular phosphoryl

290 Using mass cytometry, we profiled surface and intracellular si

291 We used mass cytometry with extensive antibody panels to perform

292 Next, the integration of single-cell mass cytometry with genome-wide transcriptome analysis s

293 Here we show that mass cytometry with multiplex combinatorial tetramer sta

294 metry, a technique that couples the power of mass cytometry with spatial context, thereby mapping cel

295 In vivo, imaging mass cytometry with TePhe visualizes translation dynamic

296 This study combined single-cell mass cytometry with the multiplex analysis of relevant p

297 ied by combining highly dimensional flow and mass cytometry with transcriptomic analyses.

298 We integrated mass cytometry with viSNE to map healthy and cancerous b

299 lurium atom allows its direct detection with mass cytometry, without postexperiment labeling.

300 These results demonstrate how standard mass cytometry workflows can be modified to perform high